Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05571956
Other study ID # AJOUIRB-SMP-2020-222
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2020
Est. completion date February 28, 2025

Study information

Verified date October 2022
Source Ajou University School of Medicine
Contact Min Jae Yang, MD, PhD
Phone 82-31-219-7821
Email creator1999@hanmail.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Organoid has emerged as the novel platform for preclinical anticancer drug testing in pancreatic ductal adenocarcinoma (PDA). However, most organoid models are not reconstituted with a tumor microenvironment. This study aimed to simultaneously establish PDA organoids and cancer-associated fibroblasts (CAFs) using endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) samples.


Description:

Despite recent advances in molecular diagnostics and systemic cancer treatment, pancreatic ductal adenocarcinoma (PDA) still shows a late-stage presentation and has a lethal prognosis, with a 5-year survival of 9% in the United States and 12.2 % in South Korea. PDA is featured with abundant desmoplastic tumor stroma derived primarily from cancer-associated fibroblast (CAF), the most effective cell within the tumor microenvironment (TME). CAFs modulate cancer invasion and metastasis through extracellular matrix remodeling, holistic signaling interplay with cancer cells by soluble secreted factors, and crosstalk with infiltrating immune cells. Therefore, CAFs are an indispensable factor in understanding PDA biology. In cancer precision medicine, organoid technology which is three-dimensional culture models grown from human cancer stem cells has recently emerged as a promising drug screening platform for standard and novel therapeutics, because it recapitulates biological features and genomic heterogeneity of original cancer. However, most current organoid models are not reconstituted with an intact TME, and the lack of a TME risks biasing tumor biology, leading to a phenotypic discrepancy between the organoid model and the original tumor. To overcome this limitation, the co-culture of cancer organoids with various TME elements, the so-called mixed organoid, is being investigated. Representatively, the patient-derived organoid models comprising tumor epithelium and endogenous tumor-infiltrating immune cells including T, B, NK cells, and macrophages were established in diverse cancer by means of an air-liquid interface culture system. This model is promising as a preclinical screening platform for novel immune therapies including immune checkpoint inhibitors. In the bladder cancer field, a new concept-cancer organoid, named bladder cancer 'assembloids', comes into the spotlight. In this organoid platform, bladder tumor organoids were three-dimensionally reconstituted with multiple stromal components including CAFs, endothelial cells, immune cells, and outer muscle layer, forming a mature bladder-like layered structure. This model demonstrated that the tumor stroma represented by CAFs prevents the shift of the tumor subtype of the organoid models to a subtype different from that of the original tumor. Recently, the investigator of this study developed a new pancreatic cancer organoid model which is integrated with fibrous TME using CAFs. This CAF-integrated pancreatic cancer organoid model retained similar genetic and pathological characteristics to those in matched human cancer tissue. In this model, it was demonstrated that CAF-cancer cell interaction promotes epithelial-mesenchymal transition of cancer cells which is known to enhance cancer metastasis. Moreover, CAFs-induced extracellular matrix deposition impairs drug delivery to cancer cells. Hence, co-culturing cancer cells, as well as CAFs, is an imperatively necessary strategy to establish a reliable preclinical organoid model for cancer precision medicine. To generate PDA mixed organoid model, the acquisition of sufficient cancer and stromal tissue is a prerequisite but a demanding process. This is because 80% of the PDA patients are not operative candidates attributed to locally advanced tumor burden or systemic spread. Therefore, the resource of PDA organoid models is largely derived from endoscopic ultrasound-guided fine needle aspiration/biopsy (EUS-FNA/B). The creation of a mixed PDA organoid model from EUS-guided biopsy samples would be challenging because the amount of total tissue materials is smaller than the surgical samples, and EUS-derived samples usually contain relatively limited stromal tissue compared with cancer cells. Hence, this study is aimed to simultaneously establish the patient-derived PDA organoids as well as CAFs using EUS-FNB samples.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date February 28, 2025
Est. primary completion date February 28, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - solid pancreatic mass lesion presumed PDA on cross-sectional imaging, regardless of tumor resectability Exclusion Criteria: - inability to provide informed consent, or coagulopathy (international normalized ratio >1.5, platelet count <50,000 per mcL)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group
Pancreatic masses were sampled using a 22-gauge FNB needle. If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs

Locations

Country Name City State
Korea, Republic of Ajou University Hospital Suwon Gyeong Gi Do

Sponsors (1)

Lead Sponsor Collaborator
Ajou University School of Medicine

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary simultaneous establishment of pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts The proportion of patients with successful establishment of pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts From the EUS-FNB procedure til 2 weeks after EUS-FNB
See also
  Status Clinical Trial Phase
Recruiting NCT06065891 - Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT01774162 - EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration N/A
Recruiting NCT04164602 - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Recruiting NCT05325281 - CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma Phase 1
Completed NCT05161013 - A Proof-of-Concept Study Evaluating LINFU™ N/A
Recruiting NCT05470920 - Genetic Testing Decision Aid N/A
Recruiting NCT04099134 - PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
Completed NCT05518071 - FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 Phase 2
Withdrawn NCT04045730 - The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma. Phase 2
Recruiting NCT06160596 - Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Recruiting NCT04636788 - Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer N/A
Recruiting NCT04435067 - Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)
Recruiting NCT04571294 - Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy N/A
Recruiting NCT06451497 - Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT03472716 - The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC)
Completed NCT03532347 - Endoscopic Ultrasound Guided Tissue Sampling (The SharkBITE Study) N/A
Withdrawn NCT06090318 - Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Phase 1/Phase 2
Not yet recruiting NCT06381882 - The Role of the Human Microbiome in Patients After Pancreatic Resection.
Recruiting NCT03544255 - Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues